The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward

JAMA Intern Med. 2018 Mar 1;178(3):321-322. doi: 10.1001/jamainternmed.2017.8167.

Authors

Alison Bateman-House¹, Christopher T Robertson^{2

3}

Affiliations

¹ Division of Medical Ethics, NYU Langone Health, NYULH Working Group on Compassionate Use and Pre-Approval Access, New York, New York.
² Regulatory Science Program and James E. Rogers College of Law, University of Arizona, Tucson.
³ NYU Langone Health, NYULH Working Group on Compassionate Use and Pre-Approval Access, New York, New York.

PMID: 29356821
DOI: 10.1001/jamainternmed.2017.8167

No abstract available

MeSH terms

Compassionate Use Trials / legislation & jurisprudence*
Drug Approval / legislation & jurisprudence*
Drugs, Investigational / therapeutic use*
Health Policy / legislation & jurisprudence*
Humans
United States
United States Food and Drug Administration / legislation & jurisprudence*

Substances

Drugs, Investigational